1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
With this grant opportunity, Model Approaches to Statewide Legal Assistance Systems - Phase II(Model Approaches - Phase II), the Administration for Community Living (ACL) continues and expands its support for state leadership efforts in implementing well integrated and cost effective legal service delivery systems that maximize the impact of limited legal resources targeted to older adults in greatest need. The ultimate goal of this grant is to promote and support the continued evolution of legal service delivery systems created through Model Approaches to Statewide Legal Assistance Systems - Phase I (Model Approaches - Phase I) towards higher levels of capacity, performance, and service delivery impact. Model Approaches - Phase II will move statewide legal service delivery systems towards greater accessibility for older adults presenting “priority” legal issues; seamless systemic integration of vital low cost legal service delivery mechanisms; precise targeting and outreach to older adults in the greatest social or economic need; improved responsiveness to legal issues that emerge from elder abuse, neglect, and financial exploitation; expanded knowledge and expertise of aging and legal service providers; implementation of legal service delivery standards/guidelines, and data collection and reporting systems that measure legal program results and demonstrate tangible impact on the independence, health, and financial security of older adults.
Funding Opportunity Number: HHS-2016-ACL-AOA-LE-0130. Assistance Listing: 93.048. Funding Instrument: CA. Category: ISS. Award Amount: Up to $179K per award.
Get alerted about grants like this
Save a search for “Administration for Community Living” or related topics and get emailed when new opportunities appear.
Search similar grants →Based on current listing details, eligibility includes: Eligible applicants: State governments. Through this FOA, states previously involved in Model Approaches - Phase I are asked to present proposals to fully implement sustainable legal service delivery systems that demonstrate significant innovations in addressing priority legal issues impacting older adults most in need. Therefore, the 28 states that have previously received Model Approaches - Phase I funding, either through state units on aging or other eligible entities, and that have not been awarded a Model Approaches Phase II grant previously, will be eligible to apply under this FOA. The twenty eight (28) eligible states are: Alabama, Alaska, Connecticut, Delaware, Florida, Georgia, Kentucky, Louisiana, Maryland, Massachusetts, Missouri, Montana, Nevada, New Hampshire, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Vermont, Virginia, Washington, and West Virginia. Within an eligible state, proposals in response to this FOA will be accepted from the entity that currently houses the State Legal Assistance Developer (LAD). Each proposal must contain a detailed plan for direct and ongoing leadership involvement of the LAD in the design, implementation, evaluation, and sustainability of the Model Approaches - Phase II legal service delivery system. Further, each proposal must contain a detailed plan for ongoing collaboration between the LAD and key partners and stakeholders involved in all aspects of project design, implementation, evaluation, and sustainability. Foreign entities are not eligible to compete for, or receive, awards made under this announcement. Cost sharing or matching funds are required. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Up to $179K per award Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is April 25, 2016. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
The Administration on Intellectual and Developmental Disabilities (AIDD) within the Administration for Community Living (ACL), U.S. Department of Health and Human Services (HHS), announces the availability of Fiscal Year (FY) 2015 funds authorized under Section 301 of the Public Health Service Act (42 U.S.C. §§ 241, 247b(k)(2)). Funds will be awarded to support a national Paralysis Resource Center (PRC) that will improve the health and quality of life of individuals living with paralysis of all ages, their families and caregivers by raising awareness of and facilitating access to a broad range of services relevant to individuals with paralysis. The PRC will work to remove environmental barriers to health for individuals living with paralysis and expand the knowledge base of proven, successful health promotion strategies leading to improved physical and emotional health for this population. The PRC will provide national outreach, grants to enhance community living opportunities and share information and resources targeted to people of all ages living with paralysis. The PRC will also conduct evaluation projects that will translate evidence based promising practices to programs in community-based settings and training for health care professionals. Funding Opportunity Number: HHS-2015-ACL-AIDD-PR-0093. Assistance Listing: 93.325. Funding Instrument: CA. Category: ISS. Award Amount: Up to $6.5M per award.
The Administration on Aging (AoA) within the Administration for Community Living (ACL), U.S. Department of Health and Human Services (HHS) forecasts the possible availability of Fiscal Year (FY) 2016 funds to make two-year grants to approximately four tribal entities for chronic disease self-management education (CDSME) programming and infrastructure. Grantee Goals: Goal 1: Significantly increase the number of older adults and adults with disabilities in tribal communities who participate in evidence-based self-management programs to empower them to better manage their chronic conditions; and Goal 2: Implement innovative funding arrangements to support the CDSME programs beyond the end of the grant period. Funding Opportunity Number: HHS-2016-ACL-AOA-CS-0129. Assistance Listing: 93.734. Funding Instrument: CA. Category: HL. Award Amount: $50K – $150K per award.
The Administration on Aging (AoA) within the Administration for Community Living (ACL), U.S. Department of Health and Human Services (HHS) forecasts the possible availability of Fiscal Year (FY) 2016 funds to make two-year grants to approximately four tribal entities for evidence-based falls prevention programming and infrastructure. Grantee Goals: Goal 1: Significantly increase the number of tribal older adults and older adults with disabilities at risk of falls in who participate in evidence-based community programs to reduce falls and falls risks; and Goal 2: Implement innovative funding arrangements to support the evidence-based falls prevention programs beyond the end of the grant period. Funding Opportunity Number: HHS-2016-ACL-AOA-FP-0133. Assistance Listing: 93.761. Funding Instrument: CA. Category: HL. Award Amount: $50K – $150K per award.
The nasal mucosa offers an effective target for inhaled drugs that either treat localized nasal conditions or quickly deliver drugs to the systemic circulation [1–3]. While nasal spray drug product designs can vary considerably between innovators, most sprays are formulated as either a homogeneous solution or a heterogeneous suspension; in the latter case, solid drug particles are dispersed within a carrier liquid [4]. Despite the many advancements in nasal drug delivery, effectively administering drugs via this route still poses many challenges. One of the main challenges relates to mucociliary motion, which tends to transport and clear drug particles from the nasal cavity after deposition, limiting the available time for drug absorption at the intended site of action [5-8].Many previous nasal spray models have considered solution formulations, where the active drug is already dissolved into a carrier liquid [9-11]. These computational fluid dynamics (CFD) models of nasal spray transport are currently well-developed and show good agreement with in vitro depositional data, but stop at the point of droplet deposition [12-19]. When considering a suspension-type formulation, an accurate model requires simulations of spray droplet transport along with the dissolution of the suspended drug particles in the nasal mucus, during which time mucociliary clearance is occurring. In cases where inhaled particles are either very large or insoluble in mucus, insufficient dissolution may result in reduced drug delivery to the nasal epithelium, reducing the overall effectiveness of the drug product [1,2,20,21]. A recently developed model demonstrates the effects of mucociliary clearance on drug absorption from a suspension formulation [22]. However, this model only considered a flattened surface representation of the nasal cavity, and was therefore unable to show uptake in specific nasal regions (e.g., the olfactory region). To study targeted nasal therapies, it is desirable to model drug uptake in an anatomically-realistic, three-dimensional model.Finally, the effects of interindividual variability on nasal drug delivery and clearance have not been fully quantified. Studies have shown that differences in individual nasal geometry can have a large impact on airflow patterns [26], but the full extent of mucus properties, impaired mucociliary function, or general inflammatory disease states on drug delivery have not been completely explored. Because many nasal spray drug products are used to treat medical conditions that cause variations from a "healthy" state, it is important to quantify how these various factors may influence the overall efficacy of nasal sprays.ObjectivesThe objective is to study the three-dimensional effects of mucociliary clearance on localized drug absorption in respiratory airways, particularly the nasal cavity, utilizing a computational modeling approach. The model should be adaptable to cases of intersubject variability, which may include variations in mucociliary clearance rates, changes in nasal geometry, and the presence of relevant disease states (e.g., nasal inflammation, changes in mucus properties, etc.). The desired outcome is a computational methodology that predicts regional absorption of inhaled drugs, particularly those whose formulations include solid or suspended drug particles and may target specific nasal regions.Detailed DescriptionA computational modeling approach will be developed to study the effects of nasal mucociliary clearance on inhaled drug absorption and the changes that result from differences in drug formulation, disease states, and interindividual anatomical differences. The model should consider realistic three-dimensional nasal airway geometries and account for device effects, inhalation, particle/droplet deposition, and, importantly, drug dissolution and absorption at the epithelium. The approach should provide a direct interface between the mucociliary clearance model and CFD simulations of spray deposition.The physiological model should consider the entire nasal airway from the nostril to the throat; variations to the geometry, representative of interindividual differences, should also be considered. The mucociliary clearance model should be general enough to allow for changes in mucus properties and clearance rates based on healthy and disease states.A straight-forward approach would utilize CFD simulations of inhalation and spray/particle transport to provide regional deposition data, while the three-dimensional mucociliary clearance model would demonstrate localized drug absorption and indicate the efficacy of drug products that target specific nasal regions. Since the development of the methodology for creating the three-dimensional CFD mucociliary clearance model is considered a primary outcome of this research, it is expected that the methodology would be made available to the FDA and preferably to the public as well in such a way that it may be reproduced, either through detailed publication of the methodology and/or through sharing of codes, models, etc. Validation of the CFD simulations with in vitro or in vivo data should be included, which should demonstrate similarity between predicted local mucociliary clearance and in vivo clearance of drug particles. If possible, it is preferable that the model be validated against multiple drug products. All relevant physics should be considered in the model; these physics may include (but are not limited to) spray turbulence, Lagrangian droplet/particle transport, mucus properties, mucociliary clearance, particle dissolution, and drug partitioning between the mucus and nasal epithelium. The proposal can include specific drug products to be studied; however, after award, the selection of drug products will be revisited in a collaborative discussion with the FDA. Suspension formulations or insufflation studies would be encouraged.The study should consist of four phases:Phase 1: Selection, identification, and construction of physiological models and inhalation patterns that will best characterize interindividual variability.Phase 2: Development and validation of the computational fluid dynamics model and mucociliary clearance model.Phase 3: Performance of simulations and post-processing of simulation data.Phase 4: Overall assessment of the relationship between drug product formulation, mucociliary clearance, interindividual variability, and regional drug absorption.Phase 5: Preparation of manuscripts, which is intended to be done in the third year of the grant, and is the reason for the reduced budget for that year. This phase may also begin earlier than the third year.References[1] HR Costantino, L Illum, G Brandt, PH Johnson, and SC Quay: Intranasal delivery: Physicochemical and therapeutic aspects. Intl J Pharma. 2007;337:1–24.[2] AA Hussain: Intranasal drug delivery. Adv Drug Deliv Rev. 1998;29:39–49.[3] S Turker, E Onur, and Y Ozer: Nasal route and drug delivery systems. Pharma World Sci. 2004;26:137–142.[4] SA Shah, RL Berger, J McDermott, P Gupta, D Monteith, A Connor, and W Lin: Regional deposition of mometasone furoate nasal spray suspension in humans. Allergy Asthma Proc. 2015;36:48–57.[5] FA Fry, and A Black: Regional deposition and clearance of particles in the human nose. J Aerosol Sci. 1973;4:113–124.[6] DF Proctor, and G Lundqvist: Clearance of inhaled particles from the human nose. Arch Int Med. 1973;131:132–139.[7] NGM Schipper, JC Verhoef, and FWHM Merkus: The nasal mucociliary clearance: Relevance to nasal drug delivery. Pharm Res. 1991;8:807–814.[8] AG Beule: Physiology and pathophysiology of the paranasal sinuses. GMS Curr Topics Otorhinolaryngol Head Neck Surg. 2010;9.[9] JD Suman, BL Laube, and R Dalby: Comparison of nasal deposition and clearance of aerosol generated by a nebulizer and an aqueous spray pump. Pharma Res. 1999;16:1648–1652.[10] J Hardy, S Lee, and C Wilson: Intranasal drug delivery by spray and drops. J Pharmacy Pharmacol. 1985;37:294–297.[11] PG Djupesland, A Skretting, M Winderen, and T Holand: Breath actuated device improves delivery to target sites beyond the nasal valve. Laryngoscope. 2006;116:466–472.[12] Y Liu, EA Matida, and MR Johnson: Experimental measurements and computational modeling of aerosol deposition in the Carleton-Civic standardized human nasal cavity. J Aerosol Sci. 2010;41:569–586.[13] K Inthavong, Q Ge, CMK Se, W Yang, and JY Tu: Simulation of sprayed particle feposition in a human nasal cavity including a nasal spray device. J Aerosol Sci. 2011;42:100–113.[14] JD Schroeter, JS Kimbell, and B Asgharian: Analysis of particle deposition in the turbinate and olfactory regions using a human nasal computational fluid dynamics model. J Aerosol Med. 2006;19:301–313.[15] H Shi, C Kleinstreuer, and Z Zhang: Modeling of inertial particle transport and deposition in human nasal cavities with wall roughness. J Aerosol Sci. 2007;38:398–419.[16] JD Schroeter, GJM Garcia, and JS Kimbell: Effects of surface smoothness on inertial particle deposition in human nasal models. J Aerosol Sci. 2011;42:52–63.[17] J Xi, X Si, JW Kim, and A Berlinski: Simulation of airflow and aerosol deposition in the nasal cavity of a 5-year-old child. J Aerosol Sci. 2011;42:156–173.[18] SM Wang, K Inthavong, J Wen, JY Tu, and CL Xue: Comparison of micron- and nanoparticle deposition patterns in a realistic human nasal cavity. Resp Physiol Neurobiol. 2009;166:142–151.[19] JS Kimbell, RA Segal, B Asgharian, BA Wong, JD Schroeter, JP Southall, CJ Dickens, G Brace, and FJ Miller: Characterization of deposition from nasal spray devices using a computational fluid dynamics model of the human nasal passages. J Aerosol Med. 2007;20:59–74.[20] P Arora, S Sharma, and S Garg: Permeability issues in nasal drug delivery. Drug Discov Today. 2002;7:967–975.[21] L Illum: Nasal drug delivery: New developments and strategies. Drug Discov Today. 2002;7:1184–1189.[22] Rygg Alex and Longest P. Worth: Absorption and Clearance of Pharmaceutical Aerosols in the Human Nose: Development of a CFD Model. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2016;29(5):416-431.[26] Zhao, Kai and Scherer, Peter W and Hajiloo, Shoreh A and Dalton, Pamela. Effect of Anatomy on Human Nasal Air Flow and Odorant Transport Patterns: Implications for Olfaction. Chemical Senses. 2004;29(5):365-379. Funding Opportunity Number: RFA-FD-18-020. Assistance Listing: 93.103. Funding Instrument: CA. Category: AG,CP,FN. Award Amount: Up to $280K per award.
MAHA ELEVATE (Make America Healthy Again: Enhancing Lifestyle and Evaluating Value-based Approaches Through Evidence) Model is sponsored by Centers for Medicare & Medicaid Services (CMS). This model provides cooperative agreements to fund proposals that promote health and prevention for Original Medicare beneficiaries. It focuses on evidence-based, whole-person care approaches, including functional or lifestyle medicine interventions, not currently covered by Original Medicare, to address the chronic disease epidemic. A Letter of Intent is required by April 10, 2026.